Investment Rating - The report maintains a "Buy" rating for the company [3][15]. Core Insights - The company reported a revenue of RMB 6.67 billion for 2025, representing a year-on-year growth of 16.5%, with a net profit of RMB 827 million, up 0.8% year-on-year, aligning with expectations [6][11]. - The total global product sales reached RMB 5.82 billion in 2025, a 17.8% increase year-on-year, driven by the sales growth of key products such as Hanquyou and Hansizhuang, with overseas revenue exceeding RMB 200 million, showing over 100% growth year-on-year [7][12]. - The company is actively advancing the clinical development of innovative products, including HLX43 and HLX22, with significant trials planned for 2026 [8][13]. Financial Data and Profit Forecast - The company’s revenue is projected to grow from RMB 5.72 billion in 2024 to RMB 8.03 billion in 2028, with a compound annual growth rate (CAGR) of approximately 11.75% [9][18]. - The net profit is expected to increase from RMB 820 million in 2024 to RMB 1.105 billion in 2028, reflecting a growth rate of 33.44% in 2028 [9][18]. - Earnings per share (EPS) are forecasted to rise from RMB 1.51 in 2024 to RMB 2.03 in 2028, indicating a positive trend in profitability [9][18].

Investment Rating - The report initiates coverage with a "Strong Buy" investment rating for the company [4][8]. Core Insights - The company has a differentiated innovation pipeline with global competitiveness, showing potential to challenge current treatment standards [8][10]. - The globalization of the company is in a substantial development phase, with biosimilars continuing to expand internationally [8][10]. Financial Data and Valuation - The company’s total revenue is projected to grow from 3,215 million RMB in 2022 to 6,469 million RMB in 2026, with a compound annual growth rate (CAGR) of approximately 6% [3]. - The net profit attributable to shareholders is expected to increase from a loss of 695 million RMB in 2022 to a profit of 863 million RMB in 2026, reflecting a significant turnaround [3]. - The earnings per share (EPS) is forecasted to rise from -1.28 RMB in 2022 to 1.59 RMB in 2026, indicating strong growth potential [3]. Product Pipeline - HLX10 (PD-1 monoclonal antibody) shows significant improvement in overall survival for first-line metastatic colorectal cancer (mCRC) patients, with median progression-free survival (mPFS) of 16.8 months compared to 10.7 months for the current standard treatment [22][24]. - HLX22 (HER2 monoclonal antibody) has the potential to change the current first-line treatment for gastric cancer, with clinical studies indicating improved survival rates and manageable safety profiles [26][29]. - HLX43 (PD-L1 ADC) demonstrates excellent preclinical data and is positioned well in the competitive landscape for similar targets [2][10]. Globalization and Market Expansion - The company has successfully launched several biosimilars in over 40 countries, including the U.S. and EU, and is on track to introduce additional products like HLX11 (biosimilar to Pertuzumab) and HLX14 (biosimilar to Denosumab) in international markets [8][10]. - The company’s major shareholder, Fosun Pharma, provides a strong backing, enhancing its market position and operational capabilities [16][10].